Tokyo, Oct. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063241) titled 'Barriers and Facilitators to Physical Activity Among Adult Women with Breas... Read More
Tokyo, Oct. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063150) titled 'Validation of blood preservation and transport conditions for standardizing... Read More
Tokyo, Oct. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063066) titled 'A Study on Reducing Injection Pain During Local Anesthesia for Thread Lift'... Read More
Tokyo, Oct. 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058145) titled 'Investigation of the Immunomodulatory Effects of Continuous Consumption of ... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-0863... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy Wi... Read More
Singapore, Oct. 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Ver... Read More